Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy
Search Results
Champions in myeloma research: A conversation with Urvi A. Shah, M.D. M.S.
March is Myeloma Awareness Month, and it’s also Women’s History Month. So what better time to spotlight LLS-funded women scientists who are driving discovery for myeloma patients.
In this first of my two-part series on myeloma researchers, I sat down with Urvi A. Shah, MD, MS, an Assistant Attending in the Myeloma Service at Memorial Sloan Kettering Cancer Center.
LLS, advocates celebrate major state policy wins for patients
While Congress meets year-round, state legislatures typically meet only in the first half of the year. The start of the summer generally marks the end of the state sessions.
As LLS prepares for our 2024 state work, it’s important to celebrate the incredible wins we achieved at the state level in 2023.
These policies are the culmination of years of work from volunteers and LLS staff from across the organization. We hope you’ll take a moment to learn about them – and share them with your own stakeholders.
Nutrition Advice from a Dietitian & Blood Cancer Survivor
76-year-old Barbara Borrell is a woman who wears many hats – a 50+ year registered dietitian, nutrition consultant and educator, cancer advocate, volunteer with The Leukemia & Lymphoma Society, and a blood cancer survivor who has battled not one, not two, but three types of blood cancer.
MY FIRST 100 DAYS AS LLS PRESIDENT & CEO
Dear Friends,
I’m just over 100 days into my new role as President & CEO of The Leukemia & Lymphoma Society (LLS) and I want to take this moment to say how grateful and proud I am to work alongside all of you in service of blood cancer patients and their families. It’s been great meeting many of you as I travel to our regions and meet with departments throughout the country. And I look forward to meeting many more of you in the months ahead.
Moving Forward: 4 Young Blood Cancer Survivors Look Ahead
Blood cancer survivors have a unique path ahead of them—and that can feel challenging.
Questions come up: Does treatment mean I have to pause everything? Do I tell my friends or coworkers (and how)? With my medical bills, how can I afford the education I want?
The Gift of Time: Giving More Moments to Blood Cancer Patients
As we transition from one year to the next, we often reflect on milestones achieved, challenges faced, and moments shared with those we love. It’s a time to focus on what’s most important—family, community, and how we’ll spend our time going forward. At the Leukemia & Lymphoma Society (LLS), we know that time is more than just a passing moment for blood cancer patients. It’s the most valuable gift they can receive.
Justin
In March 2012, when Justin was in the sixth grade, he started to rapidly lose weight, was experiencing extreme exhaustion and night sweats. After multiple visits to the doctor but no answers, his parents finally took him to the hospital for more intensive testing, including a bone marrow biopsy. One day later they received the shocking diagnosis: acute lymphoblastic leukemia.
Why We Love Nurses (And You Should Too!)
It makes sense that at diagnosis and throughout treatment, someone diagnosed with a blood cancer will look around them for answers or support.
Refractory and Relapsed
Some patients with myeloma have refractory disease. Refractory myeloma is cancer that does not respond to treatment. After a time, almost all myeloma patients will experience relapse, which means the cancer returns after a successful course of treatment. The treatment for relapsed and refractory myeloma is affected by many factors including previous therapy, rate of relapse, patient health, and genetic abnormalities.
Treatment for Relapsed and Refractory MyelomaTreatment for relapsed or refractory myeloma may include:
Ask the Doctor Part 2: Five Questions about Lymphoma
Lymphoma survivor, Jessica Melore talks to Dr. Nichols about the Latest in Lymphoma Research and Treatment
Ask the Doctor Part 3: Five Questions about Myeloma
Myeloma Survivor, Sharon Clark Talks to Dr. Nichols about the Latest in Myeloma Research and Treatment
Targeted Therapy
Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells. Not all cancers have the same targets. Each type of targeted therapy works a little bit differently, but they all interfere with the growth and survival of cancer cells. To find the most effective treatment, your doctor may run tests to identify the genes, proteins and other factors in your cancer cells. This helps the doctor choose the most effective treatment for you based on the specific factors of your disease.
Gregory
My journey is not over yet. I was diagnosed in 2019 with triple-hit diffuse large B-cell lymphoma (DLBCL), the most fearsome of the DLBCL constellation of lymphomas. My oncologist told me that in addition to chemo, I would need, in order to survive, an autologous stem cell transplant. After three rounds of progressively heavy chemo, I had a transplant in February 2020 done with my own stem cells. I was in remission! My wife and I moved to the U.K. in 2022 where I was semi-retired, living my best life with travel, music, history, and a little work on the side.
Cayden
Cayden was only three years old when he was diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in April 2020. Before his diagnosis, Cayden was full of energy, and he loved to eat. But then he started to complain about leg pain. We first thought it was just a growth spurt, but the pain got so bad that he could not walk. He also lost his appetite. That wasn’t like him at all, and I knew something was not right. It was the height of COVID-19, but we took him to the emergency room. All of his tests came back negative.